CompletedEUCTR 2006-005674-47
Long-term efficacy and safety of agomelatine in non-depressed out-patients with Generalized Anxiety Disorder.A 26-week randomised double-blind placebo-controlled parallel group study following an ...
This historical record does not confirm current site availability.
Historical research recordMultiple countries
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with anxiety. Other eligibility criteria applied.
- Listed locations
- Denmark · Estonia and 3 more locations
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 500
- Sponsor
- Institut de Recherches Internationales Servier
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Denmark, Estonia, Finland, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2006-005674-47
- Official title
Show the full official title
Long-term efficacy and safety of agomelatine in non-depressed out-patients with Generalized Anxiety Disorder.A 26-week randomised double-blind placebo-controlled parallel group study following an ...
Get this study by email
Recruitment & locations
CompletedDenmark · Estonia · Finland
2 more locations
- Hungary
- Sweden
Questions about this study
Who is behind this study?
The study sponsor is Institut de Recherches Internationales Servier, a research institute.
Who was this study for?
This study was for people with anxiety. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
A double-blind, randomised, placebo-controlled, multicentre, relapse-prevention study with Lu AA21004 in patients with Generalised Anxiety Disorder (GAD)